Anemia

Monthly Maintenance IV Iron Safe, Effective in PD Patients

Publish Date January 17, 2020

100 mg of iron sucrose is the lowest effective monthly dose tested to date in PD patients, according to investigators.

Anemia, Hyperuricemia Linked in Chronic Kidney Disease

Publish Date January 16, 2020

Among individuals with chronic kidney disease, the presence of anemia doubled the risk for hyperuricemia.

Roxadustat Effective Regardless of Prior ESA Treatment

Publish Date January 8, 2020

Phase 3 study data show a majority of ESA-treated and ESA-naïve hemodialysis patients taking roxadustat maintained a target hemoglobin range of 10.0 to 12.0 g/dL at 18 to 24 weeks.

Review: Red Blood Cell Transfusion Still Needed to Manage CKD Anemia

Publish Date December 3, 2019

Underuse of erythropoiesis-stimulating agents (ESA) and ESA hyporesponsiveness are 2 important reasons for red blood cell transfusion, according to a recent review.

Dapagliflozin Shown to Correct Anemia in Diabetic Kidney Disease

Publish Date December 3, 2019

WASHINGTON—Dapagliflozin may correct anemia in patients with type 2 diabetes and chronic kidney disease (CKD), study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest. Bergur V. Stefansson, MD, PhD, of AstraZeneca in Gothenburg, Sweden, and colleagues analyzed pooled data from 5325 patients who had participated in 14 double-blind randomized trials comparing…

Study: Ferric Citrate Improves Iron Indices Better Than Ferrous Sulfate in CKD

Publish Date December 2, 2019

In a 12-week head-to-head study, ferric citrate significantly increased ferritin and hemoglobin levels, whereas ferrous sulfate did not, investigators reported.

Functional Iron Deficiency Anemia in CKD Hikes Death Risk

Publish Date December 2, 2019

WASHINGTON—Functional iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD) is associated with an increased risk for death and cardiovascular-related hospitalization, according to study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting. Absolute IDA is associated with an elevated risk of hospitalization. A team at Baylor College of Medicine…

Roxadustat Superior for Renal Anemia

Publish Date November 22, 2019

In phase 3 trials, the drug raised hemoglobin better than epoetin alfa, with improved CV safety.

Rapid Residual Kidney Function Decline in HD Ups Anemia Risk

Publish Date November 21, 2019

Greater annual declines in residual kidney function during the first year on hemodialysis are associated with increasing odds of anemia, study finds.

Study: IL-6 Inhibition Improves ESA Responsiveness

Publish Date November 19, 2019

In a phase 2 trial of hemodialysis patients resistant to erythropoietin, inhibition of the proinflammatory cytokine interleukin-6 with the monoclonal antibody ziltivekimab decreased inflammatory markers, increased hemoglobin, decreased ESA requirements and increased serum albumin.